A Study to Evaluate the Safety and Antitumor Activity in Subjects with Advanced Solid Tumors

Study identifier:CD-ON-MEDI3617-1043

ClinicalTrials.gov identifier:NCT01248949

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects with Advanced Solid Tumors

Medical condition

Advanced Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI3617, MEDI3617, MEDI3617, MEDI3617, MEDI3617, Bevacizumab, Bevacizumab, Paclitaxel, Paclitaxel, Carboplatin

Sex

All

Actual enrollment

162

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Oct 2010
Primary Completion Date: 01 Jul 2015
Study Completion Date: 01 Oct 2015

Study design

Allocation: N/A
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2017 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria